New drug cocktail targets tough CLL

NCT ID NCT03328273

Ongoing Disease control Sponsor: Acerta Pharma BV Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 15, 2026 · Updated 3 times

Summary

This early-phase trial tests two oral drugs—acalabrutinib and ceralasertib—in 12 people with high-risk chronic lymphocytic leukemia (CLL) that has stopped responding to other treatments. The main goal is to check safety and find the right dose. It is not yet known if the combination will shrink tumors or extend life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: acalabrutinib and ceralasertib (two cancer drugs taken as pills)
What this could lead to: If it works, this could point toward a new treatment option for people with hard-to-treat CLL.
What could go wrong: This is a very early, small trial (12 people) focused on safety, not proof of effectiveness. The combination may not work or could cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA

Contacts and locations

Locations

Research Site

Krakow, 30-510, Poland
Research Site

Lodz, 93-510, Poland
Research Site

Birmingham, B9 5SS, United Kingdom
Research Site

Bournemouth, BH7 7DW, United Kingdom
Research Site

Cardiff, CF14 4XW, United Kingdom
Research Site

Leeds, LS9 7TF, United Kingdom
Research Site

London, NW1 2PG, United Kingdom
Research Site

London, SE5 9RS, United Kingdom
Research Site

Nottingham, NG5 1PB, United Kingdom
Research Site

Oxford, OX3 7LJ, United Kingdom
Research Site

Southampton, SO16 6YD, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.